Skip to main content
. 2020 Aug 3;20:717. doi: 10.1186/s12885-020-07204-6

Table 3.

Median OS and PFS for 39 SMZL patients separated by treatment modality

Treatment Median OS (CI 95%) Median PFS (CI 95%)
Rituximab 5.9 year (3.8-7.9) 6.0 year (4.3-7.7)
Splenectomy 13.9 year (8.4-19.4) 10.9 year (5.7-16.2)
Chemotherapy 13.5 year (5.8-21.2) 15.1 year (10.3-19.9)
p-value 0.565 0.530